Literature DB >> 33467487

PE_PGRS33, an Important Virulence Factor of Mycobacterium tuberculosis and Potential Target of Host Humoral Immune Response.

Eliza Kramarska1, Flavia Squeglia1, Flavio De Maio2,3, Giovanni Delogu2,4, Rita Berisio1.   

Abstract

PE_PGRS proteins are surface antigens of Mycobacterium tuberculosis (Mtb) and a few other pathogenic mycobacteria. The PE_PGRS33 protein is among the most studied PE_PGRSs. It is known that the PE domain of PE_PGRS33 is required for the protein translocation through the mycobacterial cell wall, where the PGRS domain remains available for interaction with host receptors. Interaction with Toll like receptor 2 (TLR2) promotes secretion of inflammatory chemokines and cytokines, which are key in the immunopathogenesis of tuberculosis (TB). In this review, we briefly address some key challenges in the development of a TB vaccine and attempt to provide a rationale for the development of new vaccines aimed at fostering a humoral response against Mtb. Using PE_PGRS33 as a model for a surface-exposed antigen, we exploit the availability of current structural data using homology modeling to gather insights on the PGRS domain features. Our study suggests that the PGRS domain of PE_PGRS33 exposes four PGII sandwiches on the outer surface, which, we propose, are directly involved through their loops in the interactions with the host receptors and, as such, are promising targets for a vaccination strategy aimed at inducing a humoral response.

Entities:  

Keywords:  infectious disease; protein structure; tuberculosis; vaccine

Year:  2021        PMID: 33467487      PMCID: PMC7830552          DOI: 10.3390/cells10010161

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  108 in total

1.  PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall.

Authors:  Alessandro Cascioferro; Giovanni Delogu; Marisa Colone; Michela Sali; Annarita Stringaro; Giuseppe Arancia; Giovanni Fadda; Giorgio Palù; Riccardo Manganelli
Journal:  Mol Microbiol       Date:  2007-11-19       Impact factor: 3.501

2.  Carbohydrate recognition by RpfB from Mycobacterium tuberculosis unveiled by crystallographic and molecular dynamics analyses.

Authors:  Flavia Squeglia; Maria Romano; Alessia Ruggiero; Luigi Vitagliano; Alfonso De Simone; Rita Berisio
Journal:  Biophys J       Date:  2013-06-04       Impact factor: 4.033

3.  Antibodies to Mycobacterium tuberculosis.

Authors:  Arturo Casadevall
Journal:  N Engl J Med       Date:  2017-01-19       Impact factor: 91.245

4.  Comparative Protein Structure Modeling Using MODELLER.

Authors:  Benjamin Webb; Andrej Sali
Journal:  Curr Protoc Bioinformatics       Date:  2016-06-20

Review 5.  Mycobacterium tuberculosis virulence: insights and impact on vaccine development.

Authors:  Giovanni Delogu; Roberta Provvedi; Michela Sali; Riccardo Manganelli
Journal:  Future Microbiol       Date:  2015-06-29       Impact factor: 3.165

6.  Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells.

Authors:  M J Brennan; G Delogu; Y Chen; S Bardarov; J Kriakov; M Alavi; W R Jacobs
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 7.  Mycobacterium tuberculosis: success through dormancy.

Authors:  Martin Gengenbacher; Stefan H E Kaufmann
Journal:  FEMS Microbiol Rev       Date:  2012-03-08       Impact factor: 16.408

Review 8.  An overview to understand the role of PE_PGRS family proteins in Mycobacterium tuberculosis H37 Rv and their potential as new drug targets.

Authors:  Laxman S Meena
Journal:  Biotechnol Appl Biochem       Date:  2014-11-11       Impact factor: 2.431

9.  Isolation and identification of membrane vesicle-associated proteins in Gram-positive bacteria and mycobacteria.

Authors:  Rafael Prados-Rosales; Lisa Brown; Arturo Casadevall; Sandra Montalvo-Quirós; Jose L Luque-Garcia
Journal:  MethodsX       Date:  2014-08-19

10.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

View more
  4 in total

Review 1.  The Role of TLR2 in Infectious Diseases Caused by Mycobacteria: From Cell Biology to Therapeutic Target.

Authors:  Wanbin Hu; Herman P Spaink
Journal:  Biology (Basel)       Date:  2022-02-05

2.  Structural Variability of Lipoarabinomannan Modulates Innate Immune Responses within Infected Alveolar Epithelial Cells.

Authors:  Hanrui Liu; Xuwen Gui; Shixing Chen; Weizhe Fu; Xiang Li; Tingyuan Xiao; Jie Hou; Tao Jiang
Journal:  Cells       Date:  2022-01-21       Impact factor: 6.600

3.  Structure based design of effective HtpG-derived vaccine antigens against M. tuberculosis.

Authors:  Alessia Ruggiero; Han-Gyu Choi; Giovanni Barra; Flavia Squeglia; Young Woo Back; Hwa-Jung Kim; Rita Berisio
Journal:  Front Mol Biosci       Date:  2022-08-11

4.  PGRS domain structures: Doomed to sail the mycomembrane.

Authors:  Rita Berisio; Giovanni Delogu
Journal:  PLoS Pathog       Date:  2022-09-01       Impact factor: 7.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.